Sail Biomedicines Welcomes Dr. Laura Sepp-Lorenzino to Its Board of Directors Sail Biomedicines, Inc., a pioneering biotechnology company at the forefront of programmable RNA-based medicines and a Flagship Pioneering-founded enterprise, today announced the appointment of Laura Sepp-Lorenzino, Ph.D., to its…
Sangamo Licenses Capsid Tech to Lilly for CNS Genomic Medicines Sangamo Therapeutics, Inc., a leader in genomic medicine, has entered into a new licensing agreement with Eli Lilly and Company (“Lilly”), a global pharmaceutical powerhouse, to advance treatments for neurological…
Endeavor BioMedicines Welcomes ILD Expert Dr. Lisa Lancaster as Chief Medical Officer Endeavor BioMedicines, a clinical-stage biotechnology company dedicated to developing groundbreaking treatments for life-threatening diseases, has announced the appointment of Lisa Lancaster, M.D., as its new Chief Medical Officer.…
Nosis Biosciences and Daiichi Sankyo Partner to Advance RNA Medicines Nosis Biosciences, an AI-driven biotechnology company specializing in RNA therapeutics for challenging cell types, has announced a Research Collaboration and Option Agreement with Daiichi Sankyo. This collaboration aims to leverage…
Orbis Medicines Appoints Industry Veteran Mikael Dolsten as Board Chair Orbis Medicines, a pioneering leader in oral macrocycle drug discovery, has announced the appointment of Mikael Dolsten, M.D., Ph.D., as Chairperson of the Board of Directors. Dr. Dolsten, the former…
Blueprint Medicines Corporation recently unveiled its 2025 corporate outlook and strategic vision for sustained growth, leveraging its established research, development, and commercial expertise. According to Kate Haviland, Chief Executive Officer of Blueprint Medicines, the company enters 2025 stronger than ever,…
Revolution Medicines, a clinical-stage oncology company focused on developing targeted therapies for patients with RAS-addicted cancers, recently announced the successful closing of its upsized underwritten public offering. The offering comprised 16,576,088 shares of common stock, priced at $46.00 per share,…
Blueprint Medicines Corporation presented compelling new data at the 66th American Society of Hematology (ASH) Annual Meeting, showcasing the long-term benefits of AYVAKIT® (avapritinib) in treating systemic mastocytosis (SM). These findings reflect the company’s commitment to transforming patient care through…
Senegal and Rwanda have joined an elite group of African nations by achieving Maturity Level 3 (ML3) status in the World Health Organization’s (WHO) global classification of national regulatory authorities. This milestone reflects their dedication to providing safe, effective, and…
Revolution Medicines a clinical-stage oncology company focused on developing therapies for RAS-addicted cancers, has announced the pricing of its upsized public offering. The offering consists of 14,130,436 shares of common stock at a public offering price of $46.00 per share…
Revolution Medicines a clinical-stage oncology company developing targeted therapies for RAS-driven cancers, announced significant clinical updates from its RAS(ON) inhibitor portfolio. The data, presented during an investor webcast, focused on the Phase 1 RMC-6236 monotherapy study in pancreatic ductal adenocarcinoma…
On World Children’s Day, the Global Accelerator for Paediatric Formulations Network (GAP-f) highlighted the urgent need for better access to essential medicines for children, particularly in low-resource settings. Despite their vulnerability, children often lack access to age-appropriate medications due to…